Brodalumab is a human monoclonal IgG2 antibody directed at the IL-17 receptor. The IL-17 protein family is a group of six pro-inflammatory cytokines (IL17A-F) produced by T-helper cells (Th17) thought to play an important role in autoinflammatory diseases such as psoriasis, PsA, rheumatoid arthritis, and multiple sclerosis.